Case studies
Our success is defined by our culture and shared ambition to create a positive impact, here you can find our caser studies which really showcase the best of our Commitment and our Purpose.
Croda supports Pfizer-BioNTech COVID-19 vaccine
Avanti, a company we acquired in 2020, has a strong track record in supplying R&D quantities of lipid-based drug delivery technologies to pharmaceutical companies including those developing mRNA drugs...
Diversity and inclusion
In 2021 we defined a D&I roadmap identifying actions, regarding diversity and inclusion, in five key areas.
Reforestation
Revitalising ecosystems, improving biodiversity and creating social and economic benefits for local communities.
Driving innovation in the Agriculture market
Through Croda’s acquisition of the Incotec Seed Enhancement business in 2015 and the Plant Impact Biostimulants business in 2018, we are well placed to address some of the challenges in the adoption...
Responsible business
/Images/Corporate/Corporate V2/Sustainability/Our commitment sustainability image
Externally validated avoided emissions
The emissions savings of this new product were revealed during its sustainability assessment, part of the new way of working for our innovation teams to support our Commitment.
1.5°C science-based target validation
In July 2021 we became only the third major chemical company globally to have a 1.5ºC science-based target validated.
Supplying delivery systems to help prevent cardiovascular disease
Nucleic acid-based therapies are the next big blockbuster drug class opening up exciting applications such as gene editing, where a patient’s genetic material can be modified to correct a disorder.
Focusing on D&I in Asia
Colleagues in Asia have been leading a programme of raising awareness, building an inclusive culture, and driving inclusivity in recruitment.
Supporting the next generation of therapeutic vaccines
Vaccine adjuvants are used to enhance immune response to an antigen, improving the overall efficacy of the vaccine and increasing protection against the target disease.
Human Performance programme
Our behavioural safety improvement programmes were standardised into a Group-wide Behavioural Safety Observation programme, implemented across all manufacturing sites since 2015.
Sustainability without compromise ChromaPur
Small, manufactured plastic particles, known as microbeads, are used in a wide range of cosmetic and personal care products, with research suggesting that 87% of products from the ten best-selling...
Sustainable ways of working in R&D
We are focused on aligning the work of our global R&D teams with the United Nations Sustainable Development Goals (SDGs).
Improving the customer experience in China
Our .CN website transformation, which was launched in 2020, has created an entirely new online experience for customers in fast-growing Chinese markets.
Symiro™ biostimulant
As the challenge to feed our growing global population continues, increasing crop growth and yields is becoming an important area of focus to meet the rising demand for food.
Investing in mRNA and gene therapy
As the core of our lipid systems capability within the Health Care business, Avanti is primarily focused on developing innovative lipid-based products of unparalleled purity to address specific...
Transition to bio-based MPG
Transitioning our raw materials to bio-based sources will enable us to make a significant positive impact.
Investing in organic expansion in Agriculture
Atlox 4913TM is valued by customers for creating stable dispersions in complex crop formulations, ensuring consistent distribution of actives and preventing formulation breakdown.
Uni of Cambridge case study
Working with technology designers NiTech Solutions and The University of Cambridge’s Institute for Manufacturing, we created a new process to manufacture more sustainable surfactants. Traditionally,...